03.02.2025Touchlight, a pioneering leader in synthetic DNA technology, is pleased to announce the appointment of Will Downie as a key adviser to support its mission in advancing genetic medicines. Downie’s extensive experience as an industry leader delivering strategic business growth across pharmaceutical services and product development positions him as a valuable contributor in further driving Touchlight’s synthetic DNA platforms forward.
04.02.2025According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the...
03.02.2025According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the...
03.02.2025Cormica, a global leader in life sciences testing and consulting, has completed the acquisition of Zwisler Laboratorium, a premier provider of laboratory services headquartered in Reichenau, Germany.
30.01.2025Cormica, a global leader in life sciences testing and consulting, has completed the acquisition of Zwisler Laboratorium, a premier provider of laboratory services headquartered in Reichenau, Germany.
04.02.2025MIMETAS, a global leader in human disease modeling, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. This innovative platform debuts at SLAS 2025 as a key addition to MIMETAS’ service portfolio.
05.02.2025Vorläufige Geschäftsergebnisse für 2024: Umsatz bei 3.381 Millionen Euro (+0,1 Prozent wechselkursbereinigt), operative Ertragsmarge erreicht 28,0 Prozent
30.01.2025Vorläufige Geschäftsergebnisse für 2024: Umsatz bei 3.381 Millionen Euro (+0,1 Prozent wechselkursbereinigt), operative Ertragsmarge erreicht 28,0 Prozent
03.02.2025Vorläufige Geschäftsergebnisse für 2024: Umsatz bei 3.381 Millionen Euro (+0,1 Prozent wechselkursbereinigt), operative Ertragsmarge erreicht 28,0 Prozent
05.02.2025ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The data showed ...
Sie sehen Artikel 19371 bis 19380 von insgesamt 19573